Human Growth Hormone for Height: HGH for Children to Grow Taller

Watching your child grow is one of the most visible signs of healthy development. While every child grows at their own pace, consistent growth over time is what matters most. When growth slows significantly or falls outside expected patterns, it may indicate an underlying medical issue rather than normal variation.

One of the most important conditions to identify early is growth hormone deficiency (GHD)—a disorder in which the body does not produce enough growth hormone to support normal childhood growth and development. When properly diagnosed, recombinant human growth hormone therapy can help improve growth velocity and support a child in reaching more of their genetically determined height potential.

However, not every child who is short or growing slowly has growth hormone deficiency. Constitutional growth delay, familial short stature, nutritional deficiencies, thyroid disorders, chronic medical conditions, delayed puberty, and other factors can also affect childhood growth. This is why a comprehensive evaluation is important before considering treatment.

This guide explains how growth hormone works, how deficiency is diagnosed, what HGH treatment involves, how children are monitored, and what families can realistically expect from therapy.

How Growth Hormone Affects Height

Human growth hormone (HGH), also called somatotropin, is produced by the pituitary gland, a small but critical structure located at the base of the brain.

Rather than being released continuously, growth hormone is secreted in pulses throughout the day and night, with some of the largest pulses occurring during deep sleep.

Its effects on childhood growth are mediated largely through a secondary messenger:

• HGH signals the liver and other tissues
• The liver produces IGF-1 (Insulin-Like Growth Factor-1)
• IGF-1 helps stimulate cartilage cells within the growth plates
• Growth plates contribute to the lengthening of long bones during childhood and adolescence

Growth plates are areas of developing cartilage located near the ends of long bones. While these plates remain open, bones have the potential to lengthen.

As children progress through puberty, increasing sex hormone exposure gradually causes the growth plates to mature and eventually fuse. Once the growth plates are completely closed, HGH cannot make the long bones grow longer.

When growth hormone signaling is inadequate during childhood, normal stimulation of the growth plates can be reduced—and growth velocity may slow.

What Is Growth Hormone Deficiency?

Growth Hormone Deficiency (GHD) occurs when the pituitary gland does not produce or release enough growth hormone to support normal growth.

Childhood GHD may be:

• Congenital — present from birth due to genetic or structural abnormalities
• Acquired — developing later because of conditions affecting the hypothalamus or pituitary gland, including tumors, trauma, surgery, radiation, or certain illnesses
• Idiopathic — growth hormone deficiency is identified, but the underlying cause cannot be determined

It is important to distinguish GHD from Idiopathic Short Stature. Children with idiopathic short stature are significantly shorter than expected but do not necessarily have growth hormone deficiency.

Children with true GHD often grow at a significantly slower rate than expected based on their age, pubertal stage, previous growth pattern, and family height potential.

Without appropriate treatment, some children with untreated GHD may remain substantially below their expected adult height.

Growth Hormone Deficiency vs. Being Naturally Short

Being short does not automatically mean a child has a hormone disorder.

Some healthy children are shorter because their parents are shorter. Others have constitutional growth delay, sometimes described as being a “late bloomer.” These children may grow more slowly during certain periods but have delayed skeletal maturation that gives them additional time to grow.

Doctors therefore evaluate more than a child's current height.

Important factors include:

• Current height percentile
• Changes in height percentile over time
• Annual growth velocity
• Mid-parental or genetic target height
• Pubertal development
• Bone age
• IGF-1 and other laboratory findings
• Birth history
• Nutrition
• Chronic illnesses and medications

A child who remains consistently at a lower percentile while maintaining an appropriate growth velocity may be less concerning than a child who was previously at the 50th percentile and progressively falls to the 25th, 10th, and then 5th percentile.

The pattern of growth over time is often more informative than one height measurement.

Signs a Child May Need Evaluation

Doctors pay particular attention to poor growth velocity rather than height alone.

A pediatric growth evaluation may be appropriate when a child:

• Has unusually slow annual height gain
• Drops across major percentiles on the growth chart
• Is substantially shorter than expected for family height
• Appears physically younger than peers
• Has delayed tooth eruption or delayed puberty
• Develops increased abdominal fat with relatively thin extremities
• Was born small and did not experience expected catch-up growth
• Was small for gestational age and remains significantly short
• Has headaches, vision changes, excessive thirst, or other symptoms that could suggest pituitary involvement
• Has a known medical condition that may interfere with normal growth

Growth rates vary with age, so a single cutoff does not apply to every child. Growth should be interpreted according to age, sex, pubertal stage, and previous growth pattern.

Early identification matters because the opportunity to increase final height becomes progressively smaller as skeletal maturation advances and growth plates approach closure.

What Causes Growth Hormone Deficiency in Children?

In many children, the exact cause of GHD is never identified. In others, doctors may identify a condition affecting the hypothalamus or pituitary gland.

Possible causes include:

• Congenital pituitary abnormalities
• Genetic conditions affecting growth hormone production
• Pituitary or brain tumors
• Head trauma
• Central nervous system infections
• Brain surgery
• Radiation involving the brain
• Structural abnormalities of the hypothalamic-pituitary region

Some children may also have deficiencies involving additional pituitary hormones. For this reason, evaluation may include thyroid hormones, cortisol-related testing, pubertal hormones, and other laboratory studies depending on the child's presentation.

The Diagnostic Process for HGH Deficiency

HGH therapy should not be started based on height alone. Diagnosis requires a structured growth evaluation.

Step 1: Growth Chart Analysis

Doctors review long-term growth trends rather than relying on a single measurement.

Ideally, several accurate height measurements taken over time are compared. This allows the clinician to calculate growth velocity, usually expressed in centimeters or inches per year.

The child's growth pattern can then be compared with expected growth for their age and stage of puberty.

Step 2: Medical and Family History

Evaluation should also consider:

• Birth weight and length
• Pregnancy and delivery history
• Previous illnesses
• Current medications
• Nutritional intake
• Sleep
• Timing of puberty
• Parents' heights
• Family history of delayed puberty or short stature

These details help distinguish hormonal growth disorders from normal familial or constitutional patterns.

Step 3: Laboratory Testing

Initial laboratory evaluation may include:

• IGF-1
• IGFBP-3
• Thyroid function tests
• Complete blood count
• Metabolic testing
• Screening for nutritional deficiencies
• Screening for chronic inflammatory or gastrointestinal disorders when clinically appropriate

IGF-1 is useful because growth hormone itself is released in pulses. A random growth hormone blood level therefore usually cannot diagnose or exclude GHD.

Importantly, a low IGF-1 does not automatically prove growth hormone deficiency. IGF-1 can also be affected by age, puberty, nutrition, chronic illness, thyroid function, and other factors.

Step 4: Bone Age X-Ray

A bone age study, usually performed with an X-ray of the left hand and wrist, estimates skeletal maturity and compares it with chronological age.

A delayed bone age can indicate that additional growth potential remains, but delayed bone age by itself does not diagnose GHD.

Bone age is interpreted alongside growth velocity, pubertal development, laboratory testing, and family growth patterns.

Step 5: Growth Hormone Stimulation Testing

When the history, growth pattern, and screening tests raise sufficient concern for GHD, growth hormone stimulation testing may be recommended.

Because GH secretion is pulsatile, stimulation testing evaluates how the pituitary responds after medications are administered to provoke growth hormone release.

Results must be interpreted carefully because diagnostic thresholds can vary according to the testing protocol, laboratory assay, pubertal status, and clinical circumstances.

Step 6: Additional Testing When Needed

Children with confirmed or strongly suspected GHD may require additional evaluation, which can include imaging of the hypothalamic-pituitary region and testing of other pituitary hormones.

The exact workup depends on the child's medical history and findings.

What Is HGH Therapy?

HGH therapy uses recombinant human growth hormone (somatropin). Recombinant HGH has the same amino-acid sequence as naturally produced human growth hormone and is used to replace or supplement inadequate growth hormone activity.

Administration

Treatment is generally given as a subcutaneous injection, using a small needle that delivers medication into the fatty tissue beneath the skin.

Depending on the prescribed product and indication, therapy may involve:

• Daily injections
• Often evening administration for daily formulations
• Rotating injection sites
• In some circumstances, an FDA-approved long-acting growth hormone formulation given less frequently

Unlike oral supplements or over-the-counter “HGH boosters,” prescription recombinant growth hormone provides actual growth hormone and requires medical supervision.

Growth hormone is a peptide hormone and cannot simply be taken as a conventional oral supplement because it would be broken down during digestion.

How Is HGH Dose Determined for a Child?

There is no single HGH dose appropriate for every child.

Pediatric dosing may depend on:

• Body weight
• Diagnosis
• Age
• Pubertal status
• Growth response
• IGF-1 levels
• Side effects
• The specific growth hormone product being prescribed

Children should therefore be monitored throughout therapy rather than remaining indefinitely on an unchanged dose.

As a child gains weight, enters puberty, or experiences changes in IGF-1 levels, the treatment plan may need to be adjusted.

What HGH Treatment Aims to Achieve

The purpose of HGH therapy is not to create excessive or unnatural height.

For a child with medically appropriate indications, treatment may aim to:

• Restore or improve growth velocity
• Promote appropriate linear growth
• Support bone and body composition development
• Reduce the degree of height deficit
• Help the child move closer to their genetically expected height prediction

Treatment goals should be individualized. A child's response depends on the underlying diagnosis, age when treatment begins, skeletal maturity, genetics, puberty, adherence, and other factors.

Expected Results of HGH Therapy

One of the most common questions parents ask is, “How much taller will my child grow with HGH?”

There is no single number that applies to every child.

Response varies depending on:

• Age at treatment initiation
• Severity of growth hormone deficiency
• Underlying diagnosis
• Height deficit before treatment
• Bone age
• Pubertal stage
• Genetic height potential
• Medication adherence
• Dose and treatment duration

Children with true GHD can experience a substantial improvement in growth velocity after treatment begins. The largest acceleration frequently occurs during the first year, although individual responses vary considerably.

Parents may notice an improvement in measured growth during the first 3–6 months, but treatment effectiveness should be assessed using accurate serial measurements rather than short-term visual changes.

Treatment may continue for several years and is reassessed as the child approaches adult height and skeletal maturity.

What Happens During the First Year of HGH Treatment?

The first year is particularly important because clinicians can evaluate whether a child is responding appropriately.

Follow-up typically focuses on:

• Change in height
• Annualized growth velocity
• Weight
• Pubertal progression
• IGF-1
• Medication adherence
• Injection technique
• Side effects

A child who does not demonstrate the expected response may require reassessment of the diagnosis, dosage, adherence, nutrition, thyroid status, or other factors affecting growth.

The goal is not simply to continue treatment—it is to confirm that treatment is producing an appropriate clinical response.

Monitoring During Treatment

HGH therapy requires careful, ongoing supervision.

Children are evaluated periodically for:

• Height progression
• Growth velocity
• Weight and body composition
• IGF-1 levels
• Thyroid function when indicated
• Pubertal progression
• Symptoms or treatment side effects
• Skeletal maturation with repeat bone age studies when appropriate

A delayed bone age may change as a child grows and progresses through puberty, so bone age can sometimes be repeated during longer treatment courses.

Doses may be adjusted according to growth response, body weight, IGF-1 concentrations, the child's diagnosis, and clinical findings.

The objective is to promote an appropriate growth response while avoiding unnecessary hormone exposure.

Safety and Side Effects

Recombinant growth hormone has been used in pediatric medicine for decades. When prescribed for an appropriate indication and monitored carefully, most children tolerate treatment well.

Potential side effects can include:

• Injection-site irritation
• Swelling or fluid retention
• Joint or muscle discomfort
• Headaches
• Changes in glucose metabolism
• Changes in thyroid hormone requirements

Rare but clinically important complications can occur. Persistent or severe headaches, visual symptoms, hip or knee pain, limping, or other new concerning symptoms should be reported promptly to the treating clinician.

Children receiving HGH require ongoing medical follow-up so potential complications can be identified early.

Who Should Not Receive HGH Therapy?

Growth hormone treatment is not appropriate for every child.

Contraindications and precautions depend on the individual child and the prescribed product. Growth hormone generally should not be used to increase height once the growth plates have fused.

Certain medical conditions, including active malignancy and some acute critical illnesses, may also make treatment inappropriate.

A child's complete medical history should therefore be reviewed before therapy is prescribed.

The Importance of Timing

Timing is one of the most critical factors affecting potential height outcomes.

When medically indicated, treatment generally has more opportunity to influence height when:

• Growth plates remain open
• Significant skeletal growth remains
• Abnormal growth is recognized earlier
• Treatment can continue for an adequate period before adult height is reached

Puberty is especially important because children initially experience a pubertal growth spurt, followed by progressive growth plate maturation.

Once the growth plates have completely fused, HGH cannot restart longitudinal bone growth.

This is one reason parents should not wait until the end of adolescence to investigate a longstanding abnormal growth pattern.

Can HGH Make a Child Taller If They Do Not Have Growth Hormone Deficiency?

This question requires an important distinction.

Recombinant growth hormone is FDA-approved for several pediatric conditions in addition to classic growth hormone deficiency. Depending on the child's circumstances, these can include certain children with severe short stature or specific medical conditions.

However, being shorter than average does not automatically mean HGH treatment is appropriate.

A child should first undergo evaluation to determine:

1. Whether growth is actually abnormal
2. Why the child is short
3. How much growth potential remains
4. Whether a recognized indication for treatment exists
5. Whether potential benefits justify treatment burden and risks

The decision should be based on the child's complete clinical picture rather than a desire to achieve a particular height.

Supporting Growth Beyond Medication

HGH therapy cannot replace the basic requirements for healthy childhood development.

Even when medication is medically indicated, sleep, nutrition, physical activity, and treatment of underlying health problems remain important.

Sleep

Growth hormone secretion is closely linked with sleep, particularly slow-wave sleep.

Sleep requirements vary by age. Rather than assuming every child needs the same number of hours, families should follow age-appropriate pediatric sleep recommendations and maintain a consistent sleep schedule.

Nutrition

Adequate calories and nutrients are necessary for normal growth.

Important nutrients include:

• Protein
• Vitamin D
• Calcium
• Zinc
• Iron

More is not necessarily better. Nutritional deficiencies should be identified and corrected, but excessive supplementation does not make a healthy child grow beyond their genetic potential.

Physical Activity

Regular age-appropriate physical activity supports bone health, muscle development, cardiovascular health, and overall well-being.

Exercise itself cannot correct true growth hormone deficiency, but it is an important component of healthy development.

Emotional and Psychological Impact

Growth differences can affect more than physical development.

Some children with significant short stature may experience:

• Reduced confidence
• Teasing or bullying
• Social challenges
• Concerns about appearing younger than peers
• Difficulty with certain sports or activities

However, height does not determine a child's emotional well-being, and treatment should not be presented as necessary for confidence or social acceptance.

Families can support children by addressing both the medical aspects of abnormal growth and the child's emotional experience.

When short stature causes significant distress, psychological support may be helpful alongside medical evaluation.

Questions Parents Should Ask During a Growth Evaluation

Parents considering an evaluation may find it helpful to ask:

• What is my child's current height percentile?
• Has my child been crossing percentiles?
• What is my child's annual growth velocity?
• Is their growth appropriate for their stage of puberty?
• What is their estimated genetic target height?
• Is bone age delayed, advanced, or appropriate?
• Should IGF-1 or other laboratory testing be performed?
• Is growth hormone stimulation testing necessary?
• How much growth potential appears to remain?
• Does my child meet criteria for growth hormone treatment?
• How would treatment response be monitored?

These questions help shift the conversation away from simply asking, “Is my child too short?” and toward the more important question: “Is my child growing normally?”

Insights from Dr. Devin Stone, ND

From a clinical standpoint, one of the most important considerations is determining who truly benefits from HGH therapy.

Dr. Stone emphasizes:

“Not every short child has a deficiency. The key is identifying abnormal growth velocity—not just height.”

“Growth hormone therapy is powerful, but it should only be used when clearly indicated through appropriate evaluation and testing.”

“Parents often underestimate the importance of sleep and nutrition, which are foundational components of healthy development.”

“Earlier evaluation—when appropriate—can provide families with more options before growth plates begin closing.”

He also notes that managing expectations is critical:

“The goal is not to create extraordinary height—it’s to identify abnormal growth and help a child reach their healthy growth potential when treatment is medically appropriate.”

Final Thoughts

Human growth hormone plays a central role in childhood development, but short stature alone does not establish growth hormone deficiency.

The most important information often comes from the child's pattern over time: growth velocity, changing percentiles, bone age, pubertal development, family height, and appropriate laboratory evaluation.

When a child truly has growth hormone deficiency or another recognized indication for recombinant growth hormone, appropriately prescribed treatment can substantially improve growth.

The key is accurate diagnosis, appropriate timing, realistic expectations, and careful monitoring.

If you have concerns about your child's growth, a comprehensive evaluation can help determine whether the pattern represents normal variation, delayed development, an underlying medical condition, or a situation in which treatment should be considered.

Medically Reviewed By

Dr. Devin Stone, ND

Dr. Devin Stone, ND is a licensed naturopathic doctor and founder of HGHforChildren.com. He focuses on pediatric growth evaluation, short stature assessment, delayed puberty, bone age analysis, growth hormone deficiency screening, and growth optimization programs for children and adolescents.

Dr. Stone earned his degree from Bastyr University and helps families better understand childhood growth concerns through individualized evaluation and treatment planning. His clinical focus includes growth hormone testing, IGF-1 interpretation, bone age assessment, growth velocity monitoring, and growth-promoting interventions when medically appropriate.

Through HGHforChildren.com, Dr. Stone educates parents about childhood growth disorders, height prediction, growth velocity, skeletal maturity, and treatment options for children who may not be reaching their expected growth potential.

Learn more about Dr. Stone and schedule a consultation with our pediatric growth team.

Medical References

1. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics. 2016;86(6):361–397. doi:10.1159/000452150. This is the major Pediatric Endocrine Society guideline and is probably the most important reference for the page.
   PubMed: Pediatric Growth Hormone Treatment Guidelines
2. Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics. 2019;92(1):1–14. doi:10.1159/000502231. Excellent support for your sections on evaluating short stature, growth velocity, bone age, IGF-1, diagnosis, and treatment decisions.
   PubMed Central: Diagnosis and Treatment of Short Stature
3. Growth Hormone Research Society. Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone Deficiency in Childhood and Adolescence. Journal of Clinical Endocrinology & Metabolism. 2000;85(11):3990–3993. doi:10.1210/jcem.85.11.6984. This supports the article's discussion of comprehensive clinical assessment, growth measurements, biochemical testing, and radiologic evaluation.
   Journal of Clinical Endocrinology & Metabolism
4. Cohen P, Rogol AD, Deal CL, et al. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature. Journal of Clinical Endocrinology & Metabolism. 2008;93(11):4210–4217. doi:10.1210/jc.2008-0509. Particularly useful because your article explains the important distinction between idiopathic short stature and true growth hormone deficiency.
   PubMed: Idiopathic Short Stature Consensus Statement
5. Pediatric Endocrine Society. Growth Hormone Deficiency: A Guide for Families. Pediatric Endocrine Society/American Academy of Pediatrics Section on Endocrinology Patient Education Committee. This is a strong authoritative reference for GHD causes, IGF-1 testing, GH stimulation testing, recombinant HGH treatment, dosing principles, monitoring, and potential adverse effects.
   Pediatric Endocrine Society: Growth Hormone Deficiency
6. Pediatric Endocrine Society. Growth Hormone Deficiency, Idiopathic Short Stature, and IGF-I Deficiency Treatment Guidelines. These clinical guidelines address recombinant GH treatment in children and adolescents with GHD, ISS, and primary IGF-I deficiency and emphasize individualized assessment of benefits and risks.
   Pediatric Endocrine Society Clinical Guideline
7. Endocrine Society. Growth Hormone Deficiency. Endocrine Library. This provides additional medical support for the physiology of GH and IGF-1, evaluation using growth charts and bone age, stimulation testing, recombinant GH treatment, monitoring, and recognized adverse effects.
   Endocrine Society: Growth Hormone Deficiency
8. Endocrine Society. Growth and Short Stature. Endocrine Library. Useful support for differentiating normal short stature from pathological growth failure and for explaining the pediatric conditions for which growth hormone therapy may be considered.
   Endocrine Society: Growth and Short Stature